Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huang, Wen ^a   Xin, Guang ^a,b   Wei, Zeliang ^a   Ji, Chengjie ^c   Zheng, Huajie ^a   Gu, Jun ^a   Ma, Limei ^a   Huang, Wenfang ^c   Morris Natschke, Susan L ^b   Yeh, Jwu Lai ^d   Zhang, Rui ^a   Qin, Chaoyi ^a   Wen, Li ^a   Xing, Zhihua ^a   Cao, Yu ^a   Xia, Qing ^a   Lu, Yanrong ^a   Li, Ke ^a   Niu, Hai ^a,e   Lee, Kuo Hsiung ^b,f  

^a SICHUAN UNIVERSITY   (China)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c Affiliated Cancer Hospital of University of Electronic Science and Technology of China   (China)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e SICHUAN UNIVERSITY   (China)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECT; GENETICS; MALE; METABOLISM; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX I; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE, INBRED C57BL; MITOCHONDRIA; PLATELET ACTIVATION; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; THROMBOSIS;

EID: 84994201225     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36222     Document Type: Article

References (53)

1. Cho, N. H. et al. The IDF Diabetes Atlas 7th edition (2015).
2. Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914-918 (2008).
3. Tang, W. H. et al. Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 129, 1598-1609 (2014).
4. Creager, M. A., Lüscher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. Circulation 108, 1527-1532 (2003).
5. Vazzana, N., Ranalli, P., Cuccurullo, C. & Davì, G. Diabetes mellitus and thrombosis. Thromb. Res. 129, 371-377 (2012).
6. Randriamboavonjy, V. et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. Thromb Haemost. 114, 569-578 (2015).
7. Cannegieter, S. C. et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood 125, 229-235 (2015).
8. Inzucchi, S. E. Metformin and heart failure. Diabetes Care. 28, 2585-2587 (2005).
9. Roussel, R. et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 170, 1892-1899 (2010).
10. Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 150, 542-546 (2014).
11. Lu, D. Y. et al. Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord. 14, 187 (2014).
12. DeFronzo, R. A. et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28, 1092-1100 (2005).
13. El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 275, 223-228 (2000).
14. Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. Biochem J. 348, 607-614 (2000).
15. Barile, C. J. et al. Inhibiting platelet-stimulated blood coagulation by inhibition of mitochondrial respiration. PNAS USA 109, 2539-2543 (2012).
16. Yamagishi, S. I., Edelstein, D., Du, X. L. & Brownlee, M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 50, 1491-1494 (2001).
17. Cardenes, N. et al. Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation. Blood 123, 2864-2872 (2014).
18. 2 to promote inflammation. Blood 124, 2173-2183 (2014).
19. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem J. 417, 1-13 (2009).
20. Kwiecien, S. et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-induced gastric injury. J Physiol Pharmacol. 65, 613-622 (2014).
21. Hottz, E. D. et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. J Thromb Haemost. 11, 951-962 (2013).
22. Caparrós, E. et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 107, 3950-3958 (2006).
23. Geijtenbeek, T. B. et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575-585 (2000).
24. King, S. M. et al. Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. Circulation 120, 785-791 (2009).
25. Wang, X. et al. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost. 4, 403-410 (2006).
26. Zhang, S. et al. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation 131, 1160-1170 (2015).
27. Ballinger, S. W. et al. Hydrogen peroxide and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res. 86, 960-966 (2000).
28. Inzucchi, S. E., Masoudi, F. A. & McGuire, D. K. Metformin in heart failure. Diabetes Care. 28, 2585-2587 (2007).
29. Grant, P. J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 29, 6S44-6S52 (2003).
30. Jy, W. et al. Comparison of pharmacokinetics and hemostatic efficacy of red cell microparticles (RMP) in rabbits using different infusion regimens. Blood 124, 2811-2811 (2014).
31. Musumeci, L. et al. Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 131, 656-668 (2015).
32. Wallace, J. L. et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol. 257, 249-255 (1994).
33. Dayal, S. et al. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 127, 1308-1316 (2013).
34. Zhou, Q. et al. Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res. 133, 57-65 (2014).
35. Piel, S., Ehinger, J. K., Elmér, E. & Hansson, M. J. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol. 213, 171-180 (2015).
36. Qin, C. et al. Variation of perioperative plasma mitochondrial DNA correlate with peak inflammatory cytokines caused by cardiac surgery with cardiopulmonary bypass. J Cardiothorac Surg. 10, 85 (2015).
37. Lal, I., Dittus, K. & Holmes, C. E. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 15, 207 (2013).
38. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553-557 (2015).
39. Fitzgerald, J. R., Foster. T. J. & Cox, D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 4, 445-457 (2006).
40. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).
41. Brill, A. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117, 1400-1407 (2011).
42. Anil-Kumar, K. S. et al. Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. Eur. J Med Chem. 81, 456-472 (2014).
43. Wang, S. B. et al. Kaempferol suppresses collagen-induced platelet activation by inhibiting NADPH oxidase and protecting SHP-2 from oxidative inactivation. Free Radic Biol Med. 83, 41-53 (2015).
44. Bae, O. N. et al. Trivalent methylated arsenical-induced phosphatidylserine exposure and apoptosis in platelets may lead to increased thrombus formation. Toxicol Appl Pharmacol. 239, 144-153 (2009).
45. Schoenwaelder, S. M. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663-1674 (2011).
46. Shirakabe, A. et al. Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation 133, 1249-1263 (2016).
47. Bridges, H. R., Jones, A. J., Pollak, M. N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 462, 475-487 (2014).
48. Ouseph, M. M. et al. Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis. Blood 126, 1224-1233 (2015).
49. Gong, G. H., Qin, Y. & Huang, W. Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis CH Wright in vitro and in vivo. Phytomedicine 18, 458-463 (2011).
50. Priestley, E. S. et al. Structure-based design of macrocyclic coagulation Factor VIIa inhibitors. J Med Chem. 58, 6225-6236 (2015).
51. Citirik, M., Beyazyildiz, E., Simsek, M., Beyazyildiz, O. & Haznedaroglu, I. C. MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy. Eye 29, 376-379 (2015).
52. Nakahira, K. et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 10, e1001577 (2013).
53. Lamkanfi, M. et al. Caspase-7 deficiency protects from endotoxin-induced lymphocyte apoptosis and improves survival. Blood 113, 2742-2745 (2009).